These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Clinical development of microbicides for the prevention of HIV infection. D'Cruz OJ, Uckun FM. Curr Pharm Des; 2004 Jun 13; 10(3):315-36. PubMed ID: 14754390 [Abstract] [Full Text] [Related]
11. Effectiveness of vaginal microbicides in preventing HIV transmission. Musekiwa A, Fernando NB, Abariga SA. Trop Med Int Health; 2020 Jul 13; 25(7):790-802. PubMed ID: 32306503 [Abstract] [Full Text] [Related]
13. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials. Fichorova RN, Lai JJ, Schwartz JL, Weiner DH, Mauck CK, Callahan MM. Cytokine; 2011 Jul 13; 55(1):134-40. PubMed ID: 21530305 [Abstract] [Full Text] [Related]
14. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. N Engl J Med; 1998 Aug 20; 339(8):504-10. PubMed ID: 9709043 [Abstract] [Full Text] [Related]
16. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV. Buckheit KW, Furlan-Freguia C, Ham AS, Buckheit RW. Curr Top Med Chem; 2016 Aug 20; 16(10):1118-34. PubMed ID: 26324047 [Abstract] [Full Text] [Related]
17. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R. PLoS One; 2011 Aug 20; 6(6):e20209. PubMed ID: 21673796 [Abstract] [Full Text] [Related]